P Delanaye
Overview
Explore the profile of P Delanaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huart J, Vanderweckene P, Seidel L, Bovy C, Delanaye P, Dubois B, et al.
Acta Cardiol
. 2024 Dec;
:1-9.
PMID: 39645572
Background: Blood pressure (BP) control in haemodialysis (HD) patients is essential. Peri-dialytic BP levels do not accurately diagnose hypertension or predict the cardiovascular (CV) mortality. Methods: In this study, we...
2.
Delanaye P, Scheen A
Rev Med Liege
. 2023 Jan;
78(1):24-28.
PMID: 36634063
The inhibition of the renin-angiotensin system represents the first preventive treatment of the chronic kidney disease (CKD), especially in presence of albuminuria. Recently, sodium-glucose cotransporter type 2 inhibitors (SGLT2i, gliflozins)...
3.
Delanaye P, Dubois B, Cavalier E, Jouret F
Rev Med Liege
. 2022 Apr;
77(4):249-252.
PMID: 35389010
Chronic kidney disease (CKD) affects ~7 % of the general population and is burdened with significant morbidity and mortality, especially cardiovascular disease. At the terminal stage, CKD requires demanding and...
4.
Valdes-Socin H, Scheen A, Jouret F, Grosch S, Delanaye P
Rev Med Liege
. 2022 Mar;
77(3):175-180.
PMID: 35258866
Most physicians do not know, or do not remember, the name of phlorizin. Hence this molecule has a major historical importance because it was the precursor of gliflozins, a new...
5.
Scheen A, Delanaye P
Rev Med Liege
. 2022 Jan;
77(1):18-24.
PMID: 35029336
Both renin-angiotensin-aldosterone system inhibitors (RAASi) and sodium-glucose cotransporter type 2 inhibitors (SGLT2i, gliflozins) reduce the risk of heart failure and of progressing towards end-stage renal disease, especially in patients with...
6.
Scheen A, Delanaye P
Rev Med Liege
. 2021 Mar;
76(3):186-194.
PMID: 33682388
Sodium-glucose cotransporter type 2 inhibitors (iSGLT2 or gliflozins) exert their antidiabetic action through a specific renal mechanism, by inhibiting tubular glucose reabsorption. These agents have proven their efficacy to reduce...
7.
Erpicum P, Grosch S, Bouquegneau A, Huart J, Resimont G, Bovy C, et al.
Rev Med Liege
. 2020 Nov;
75(S1):109-114.
PMID: 33211431
The SARS-CoV-2 virus causes a respiratory distress syndrome, the main symptom of COVID-19 (for "COronaVIrus Disease 2019"). This infectious disease has been causing a major health and socio-economic pandemic since...
8.
Bovy C, Delanaye P, Jouret F, Krzesinski J
Rev Med Liege
. 2020 Jun;
75(5-6):336-343.
PMID: 32496676
Chronic kidney disease (CKD) impairs the quality of life and increases the risk for cardiovascular morbimortality. Intensive research is conducted in order to slow down CKD development and progression. During...
9.
Resimont G, Gadisseur R, Lutteri L, Krzesinski J, Cavalier E, Delanaye P
Rev Med Liege
. 2018 Oct;
73(10):519-525.
PMID: 30335258
The measurement of proteinuria is a very simple tool to screen and manage kidney diseases. Its predictive role is also relevant from a cardiovascular point of view. However, the interpretation...
10.
Scheen A, Delanaye P
Diabetes Metab
. 2017 Nov;
44(2):101-111.
PMID: 29146035
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal...